Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study
CONCLUSIONS: Telitacicept treatment reduced disease severity in patients with LN. The initial clinical trial provided supportive evidence for the effectiveness and safety of Telitacicept as a viable treatment option for LN, allowing a reduction in the daily glucocorticoid intake while maintaining a good safety profile, and improving hypocomplementation in LN management.PMID:38613741 | DOI:10.1007/s10157-024-02501-x
Source: Herpes - Category: Infectious Diseases Authors: Xiaolu Huang Fuan Lin Hongpu Chen Source Type: research
More News: Clinical Trials | Herpes | Infectious Diseases | Laboratory Medicine | Lupus | Men | Nephritis | Study